News & Updates

Show Multimedia Only

First-time seizures a warning signal for cancers

05 May 2026

First-time seizures appear to be associated with increased short-term and long-term risks of cancer, according to a population-based cohort study.

First-time seizures a warning signal for cancers

05 May 2026

Asian study: Tumour multiplicity in ICC associated with inferior OS

05 May 2026 by

In patients with intrahepatic cholangiocarcinoma (ICC), tumour multiplicity – particularly the presence of ≥4 tumours – is associated with inferior overall survival (OS), a study conducted in Hong Kong, Seoul and Shanghai has shown.

Asian study: Tumour multiplicity in ICC associated with inferior OS

05 May 2026

Romiplostim for chemo-induced thrombocytopenia delivers in phase 3 trial

04 May 2026 by

The thrombopoietin-receptor agonist romiplostim helps mitigate chemotherapy-induced thrombocytopenia, reducing related treatment modifications in patients with gastrointestinal cancers, as shown in the landmark phase III RECITE trial.

Romiplostim for chemo-induced thrombocytopenia delivers in phase 3 trial

04 May 2026

Scalp cooling reduces chemo-induced alopecia in gynaecological cancers

04 May 2026 by

Scalp cooling (or scalp hypothermia) reduces chemotherapy-induced alopecia, alleviates psychological distress, and improves quality of life (QoL) in patients with primary gynaecologic cancers receiving carboplatin plus paclitaxel, the single-centre, randomized controlled CHARM trial has shown.

Scalp cooling reduces chemo-induced alopecia in gynaecological cancers

04 May 2026

Reflux disease ups risk of colonic neoplasia

29 Apr 2026

The presence of reflux disease, no matter the type, appears to elevate the risk for colonic neoplasia, suggests a recent study.

Reflux disease ups risk of colonic neoplasia

29 Apr 2026

Original New Drug Application Approvals by US FDA (16-31 March 2026)

29 Apr 2026

New drug applications approved by US FDA as of 16-31 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 March 2026)

29 Apr 2026

ICI efficacy in lung cancer not dictated by time of treatment

27 Apr 2026 by

In lung cancer patients receiving immune checkpoint inhibitors (ICIs), survival is not necessarily better when treatment is administered in the morning vs in the afternoon, according to the i-TIMES study.

ICI efficacy in lung cancer not dictated by time of treatment

27 Apr 2026

9-valent HPV vaccine also protective in males

27 Apr 2026

The 9-valent HPV vaccine helps prevent HPV-related cancers in adolescents and young adult males, as shown in a retrospective study.

9-valent HPV vaccine also protective in males

27 Apr 2026

$Prostate cancer patients on enzalutamide may be at risk of fall, fracture$

Prostate cancer patients on enzalutamide may be at risk of fall, fracture

24 Apr 2026

A recent study has found a higher prevalence of falls and fractures in prostate cancer patients receiving enzalutamide relative to those reported in previous clinical trials and postmarketing research.

Prostate cancer patients on enzalutamide may be at risk of fall, fracture

24 Apr 2026

SONIA: Does 1L vs 2L use of CDK4/6 inhibitors improve OS in HR+, ERBB2- ABC?

24 Apr 2026 by

A phase III randomized clinical trial (RCT) of 1,050 patients with hormone receptor–positive (HR-positive), ERBB2-negative advanced breast cancer (ABC) showed that first-line (1L) use of cyclin-dependent kinase (CDK) 4 and 6 inhibitors did not improve overall survival (OS) compared with second-line (2L) use. At the same time, a post hoc subgroup analysis suggested an OS benefit with 1L use of CDK4/6 inhibitors in premenopausal patients.

SONIA: Does 1L vs 2L use of CDK4/6 inhibitors improve OS in HR+, ERBB2- ABC?

24 Apr 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

First-time seizures a warning signal for cancers

First-time seizures a warning signal for cancers

Asian study: Tumour multiplicity in ICC associated with inferior OS

Asian study: Tumour multiplicity in ICC associated with inferior OS

Romiplostim for chemo-induced thrombocytopenia delivers in phase 3 trial

Romiplostim for chemo-induced thrombocytopenia delivers in phase 3 trial

Scalp cooling reduces chemo-induced alopecia in gynaecological cancers

Scalp cooling reduces chemo-induced alopecia in gynaecological cancers

Reflux disease ups risk of colonic neoplasia

Reflux disease ups risk of colonic neoplasia

Original New Drug Application Approvals by US FDA (16-31 March 2026)

Original New Drug Application Approvals by US FDA (16-31 March 2026)

ICI efficacy in lung cancer not dictated by time of treatment

ICI efficacy in lung cancer not dictated by time of treatment

9-valent HPV vaccine also protective in males

9-valent HPV vaccine also protective in males

Prostate cancer patients on enzalutamide may be at risk of fall, fracture

Prostate cancer patients on enzalutamide may be at risk of fall, fracture

SONIA: Does 1L vs 2L use of CDK4/6 inhibitors improve OS in HR+, ERBB2- ABC?

SONIA: Does 1L vs 2L use of CDK4/6 inhibitors improve OS in HR+, ERBB2- ABC?